You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Product Overview

Combodart is indicated for the management of moderate to severe symptomatic benign prostatic hyperplasia (BPH).

Drug-disease modelling: BPH Webinar 25th September 2019

ELITE Webcast


The impact of early vs delayed initiation of combination therapy for BPH medical management

Wednesday, 25th Sept 2019 at 12pm and 6pm

Combodart is a registered trademark of the GlaxoSmithKline group of companies